RT Journal Article
SR Electronic
T1 D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.22.20159905
DO 10.1101/2020.07.22.20159905
A1 Weissman, Drew
A1 Alameh, Mohamad-Gabriel
A1 de Silva, Thushan
A1 Collini, Paul
A1 Hornsby, Hailey
A1 Brown, Rebecca
A1 LaBranche, Celia C.
A1 Edwards, Robert J
A1 Sutherland, Laura
A1 Santra, Sampa
A1 Mansouri, Katayoun
A1 Gobeil, Sophie
A1 McDanal, Charlene
A1 Pardi, Norbert
A1 Hengartner, Nick
A1 Lin, Paulo J.C.
A1 Tam, Ying
A1 Shaw, Pamela A.
A1 Lewis, Mark G.
A1 Boesler, Carsten
A1 Şahin, Uğur
A1 Acharya, Priyamvada
A1 Haynes, Barton F.
A1 Korber, Bette
A1 Montefiori, David C.
YR 2020
UL http://medrxiv.org/content/early/2020/09/12/2020.07.22.20159905.abstract
AB The SARS-CoV-2 Spike protein acquired a D614G mutation early in the COVID-19 pandemic that appears to confer on the virus greater infectivity and is now the globally dominant form of the virus. Certain of the current vaccines entering phase 3 trials are based on the original D614 form of Spike with the goal of eliciting protective neutralizing antibodies. To determine whether D614G mediates neutralization-escape that could compromise vaccine efficacy, sera from Spike-immunized mice, nonhuman primates and humans were evaluated for neutralization of pseudoviruses bearing either D614 or G614 Spike on their surface. In all cases, the G614 pseudovirus was moderately more susceptible to neutralization. The G614 pseudovirus also was more susceptible to neutralization by monoclonal antibodies against the receptor binding domain and by convalescent sera from people known to be infected with either the D614 or G614 form of the virus. These results indicate that a gain in infectivity provided by D614G came at the cost of making the virus more vulnerable to neutralizing antibodies, and that the mutation is not expected to be an obstacle for current vaccine development.Competing Interest StatementIn accordance with the University of Pennsylvania policies and procedures and our ethical obligations as researchers, we report that Drew Weissman is named on patents that describe the use of nucleoside-modified mRNA as a platform to deliver therapeutic proteins. Drew Weissman and Norbert Pardi are also named on a patent describing the use of modified mRNA in lipid nanoparticles as a vaccine platform. We have disclosed those interests fully to the University of Pennsylvania, and we have in place an approved plan for managing any potential conflicts arising from licensing of our patents.Clinical TrialNCT04380701Funding StatementBioNTech is the Sponsor of the clinical trial study that the human samples were obtained from, N.P. was supported by the NIAID -1R01AI146101, U.S, and C.B. work for BioNTech, M.L. was supported by NIAID - R01AI123738). D.W. was supported by grants from the NIAID - AI142596 and AI124429, IPCAVD - U19AI142596, and BioNTech. B.H. was funded by a contract from the State of NC funded by the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) and NIH grant IPCAVD-U19AI142596, P.A. was funded by NIAID R01 - AI145687 and a contract from the State of NC funded by the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), D.M. was funded by NIH - HHSN272201800004C, the Gates Foundation - OPP1146996 and a contract from the State of NC funded by the Coronavirus Aid, Relief, and Economic Security Act (CARES Act). B.K. was funded by the Los Alamos National Laboratory directed research (LDRD) project 20200706ER Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial was carried out in Germany in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines and with approval by an independent ethics committee (Ethik-Kommission of the Landesarztekammer Baden-Wurttemberg, Stuttgart, Germany) and the competent regulatory authority (Paul-Ehrlich Institute, Langen, Germany). All participants provided written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesI will share all primary data generated as part of this grant. It will be deposited at the National Addiction & HIV Data Archive Program (NAHDAP), which is an NIH-funded repository. Collected samples will be stored at the University of Pennsylvania and available after review of the request by the PI. https://www.icpsr.umich.edu/icpsrweb/NAHDAP/data/index.jsp